Common side effects include nausea, constipation, and appetite suppression, which typically fade within weeks
The SELECT trial builds on these results, showing that once-weekly semaglutide resulted in a 20% reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with pre-existing cardiovascular disease and BMI 27kg/m 2
Paradoxically, this means the very people who benefit most from semaglutide weight loss are also most likely to experience reflux, at least initially
For each medication, we defined a start date (date of first redemption) and an end date (date of last redemption plus the number of daily doses redeemed on that date)
This represents a unique pharmacological profile for studying receptor cross-talk
The changing faces of glutathione, a cellular protagonist